<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04408482</url>
  </required_header>
  <id_info>
    <org_study_id>3509/2019</org_study_id>
    <nct_id>NCT04408482</nct_id>
  </id_info>
  <brief_title>Does Pancreatic Stent Decrease the Risk of Pancreatitis After Pancreatic Sphincterotomy for Difficult Cannulation?</brief_title>
  <official_title>Does Pancreatic Stent Decrease the Risk of Pancreatitis After Pancreatic Sphincterotomy for Difficult Cannulation?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the risk of PEP after pancreatic sphincterotomy
      performed for difficult cannulation in a group of patients with and in a group of patients
      without placement of a prophylactic pancreatic stent. The definition of difficult cannulation
      is defined according to the literature.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-ERCP pancreatitis rate</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">268</enrollment>
  <condition>Endoscopic Retrograde Cholangiopancreatography</condition>
  <arm_group>
    <arm_group_label>Pancreatic sphincterotomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pancreatic sphincterotomy performed in difficult cannulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreatic sphincterotomy + pancreatic stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pancreatic sphincterotomy performed in difficult cannulation + pancreatic stent placement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biliary cannulation</intervention_name>
    <description>Cannulation of biliary duct by sphincterotome</description>
    <arm_group_label>Pancreatic sphincterotomy</arm_group_label>
    <arm_group_label>Pancreatic sphincterotomy + pancreatic stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive patients with na√Øve papilla presenting to ERCP with indication of common
             bile duct (CBD) cannulation will be considered to the study.

        Exclusion Criteria:

          -  Exclusion criteria are age below 18 years, acute pancreatitis and no consent to the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrea Tenca, MD, PhD</last_name>
    <phone>+358408484955</phone>
    <email>ante14@hotmail.it</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2020</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Andrea Tenca</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

